nach oben

Supportive Care in Cancer

Erschienen in:

01.05.2007 | Original Article

Amisulpride in the short-term treatment of depressive and physical symptoms in cancer patients during chemotherapies

verfasst von: Riccardo Torta, Carlotta Berra, Luca Binaschi, Roberto Borio

Erschienen in: Supportive Care in Cancer | Ausgabe 5/2007

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Amisulpride is a substituted benzamide that, at low doses, selectively blocks D2 and D3 presynaptic dopamine receptors, enhancing dopaminergic transmission in frontal cortex and limbic areas. Many clinical studies versus placebo, tricyclic antidepressants and selective serotonin reuptake inhibitors showed amisulpride antidepressant effect, supporting its safety and rapid onset of action. In oncological population, depression is quite frequent and difficult to treat because of the particular sensitivity of cancer patients to the antidepressants’ side effects.

Goals of work

The aims of this study were to evaluate efficacy, safety and tolerability of low doses of amisulpride (50 mg) in oncological, depressed patients during chemotheraphy.

Materials and methods

One hundred six consecutive cancer outpatients with depressive symptoms were treated in a prospective, intention to treat, 4-week study, and were evaluated in single-blind with Montgomery Asberg rating scale for depression (MADRS), clinical global impression (CGI) and dosage record treatment emergent symptom scale (DOTES) to assess side effects of treatment.

Main results

After 4 weeks of treatment, scores of MADRS and CGI significantly improved (p < 0.002; p < 0.001, respectively), with a reduction of depressive symptoms concerning both emotional (such as apparent sadness, reported sadness, inner tension, etc.) and physical cluster (such as lack of appetite, reduction in weight, tiredness and insomnia) with good tolerability (only two patients dropped out).

Conclusions

This study is the first trial on the use of amisulpride in a cohort of oncological, depressed patients during chemotherapy. Amisulpride demonstrated high efficacy and safety. Controlled studies are needed to confirm these preliminary data.

Amore M, Jori MC (2001) AMISERT Investigators. Faster response on amisulpride 50 mg versus sertraline 50–100 mg in patients with dysthymia or double depression: a randomized, double-blind, parallel group study. Int Clin Psychopharmacol 16(6):317–324PubMedCrossRef

Ben-Jonathan N, Liby K, McFarland M, Zinger M (2002) Prolactin as an autocrine/paracrine growth factor in human cancer. Trends Endocrinol Metab 13:245–250PubMedCrossRef

Bolis CL, Licinio J, van Drimmelen-Krabbe JJ (eds) (1997) Classification of dysthymia and related conditions in neurological disorders: recommendation for the clinical descriptions and criteria for research (version for field trials). World Health Organization, Geneva

Boyer P, Lecrubier Y, Stalla-Bourdillon A, Fleurot O (1999) Amisulpride versus amineptine and placebo for the treatment of dysthymia. Neuropsychobiology 39:25–32PubMedCrossRef

Cassano GB, Jori MC (2002) AMIMAJOR Group. Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: a randomized, double-blind, parallel group study. Int Clin Psychopharmacol 17(1):27–32PubMedCrossRef

Derogatis LR, Morrow GR, Fetting J et al (1983) The prevalence of psychiatric disorders among cancer patients. JAMA 249:751–757PubMedCrossRef

Cohen N, Alon I, Almoznino-Sarfian D, Gorelik O, Chachasvili S, Litvinjuk V, Modai D, Weissgarten J (1999) Sulpiride versus metoclopramide in nononcological patients with vomiting or nausea. Clin Gastroenterol 29(1):59–62CrossRef

Guy W (1976) Early Clinical Drug Evaluation Unit (ECDEU) Assessment Manual for Psychopharmacology. Rev. Rockville, MD, US National Institute of Mental Health, Psychopharmacology Research Branch, pp 223–244

Grassi L, Albieri G, Rosti G, Marangolo M (1987) Psychiatric morbidity after cancer diagnosis. Exp Clin Psychiatr 3:199–205

10.

Grant SC, Kris MG, Gralla RJ, Clark RA, Tyson LB (1993) Dose-ranging evaluation of the substituted benzamide dazopride when used as an antiemetic in patients receiving anticancer chemotherapy. Cancer Chemother Pharmacol 31(6):442–444PubMedCrossRef

11.

Grassi L, Travado L, Gil Moncayo FL et al (2004) Psychosocial morbidity and its correlates in patients of the Mediterranean area: findings from the Southern European Psycho-Oncology Study. J Affect Disord 83:243–248PubMedCrossRef

12.

Guslandi M (1990) Antiemetic properties of levo-sulpiride. Minerva Med 81(12):855–860PubMed

13.

Hamon-Vilcot B, Chaufour S, Deschamps C, Canal M, Zieleniuk I, Ahtoy P, Chretien P, Rosenzweig P, Nasr A, Piette F (1998) Safety and pharmacokinetics of single oral dose of amisulpride in healthy volunteers. Eur J Clin Pharmacol 54(5):405–409PubMedCrossRef

14.

Hankinson SE, Willet WC, Michaud DS, Manson JE, Colditz GA, Longcope C, Rosner B, Speizer FE (1999) Plasma prolactin levels and subsequent risk of breast in postmenopausal women. J Natl Acad Sci USA 92:3650–3657

15.

Keller VE (1995) Management of nausea and vomiting in children. J Pediatr Nurs 10(5):280–286PubMedCrossRef

16.

Kopecek M, Bares M, Svarc J, Dockery C, Horacek J (2004) Hyperprolactinemia after low dose of amisulpride. Neuro Endocrinol Lett 25(6):419–422 (Dec)PubMed

17.

Lane KE, Leav I, Ziar J, Bridges RS, Rand WM, Ho SM (1997) Suppression of testosterone and estradiol-17β-induced dysplasia in the dorsolateral prostate of Noble rats by bromocriptine. Carcinogenesis 18:1505–1510PubMedCrossRef

18.

Lecrubier Y, Boyer P, Turjanski S, Rein W (1997) Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group. J Affect Disord 43:95–103PubMedCrossRef

19.

Manni A, Boucher AE, Demers LM, Harvey HA, Lipton A, Simmonds MA, Bartholomew M (1989) Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer. Breast Cancer Res Treat 14:289–298PubMedCrossRef

20.

Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:328

21.

Nandi S, Guzman RC, Yang J (1995) Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis. Proc Natl Acad Sci USA 92:3650–3657PubMedCrossRef

22.

Racagni G, Canonico PL, Ravizza L, Pani L, Amore M (2004) Consensus on the use of substituted benzamides in psychiatric patients. Neuropsychobiology 50(2):134–143PubMedCrossRef

23.

Ravizza L, Agnoli A, Torta R, Zanalda E (1990) Amisulpride versus amitryptiline. Double blind study in dysthimic disorder. VIII World Congress of Psychiatry, Atene, October 1989. Elsevier Science Publishers, 208–213

24.

Razavi D, Delvaux N, Farvacques C, Robaye E (1990) Screening for adjustment disorders and major depressive disorders in cancer in-patients. Br J Psychiatry 156:79–83PubMed

25.

Schoemaker H, Claustre Y, Fage D, Rouquier I, Chergui K, Curet O et al (1997) Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 280:83–97PubMed

26.

Smeraldi E (1998) Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission. A double-blind, comparative study. J Affect Disord 56:47–48CrossRef

27.

Snaith RP, Harrop FM, Newby PA, Teale C (1986) Grade scores of the Montgomery–Asberg depression and the clinical anxiety scales. Br J Psychiatry 148:599–601PubMedCrossRef

28.

Steger RW, Chandrashekar V, Zhao W, Bartke A, Horseman ND (1998) Neuroendocrine and reproductive functions in male mice with targeted disruption of the prolactine gene. Endocrinology 139:3691–3695PubMedCrossRef

29.

Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347:146–151PubMedCrossRef

30.

Stattin P, Rinaldi S, Stenman UH, Riboli E, Hallmans G, Bergh A, Kaaks R (2001) Plasma prolactine and prostate cancer risk: a prospective study. Int J Cancer 92:463–465PubMedCrossRef

31.

Stiefel FC, Kornblith AB, Holland JC (1990) Changes in the prescription patterns of psychotropic drugs for cancer patients during a 10-year period. Cancer 65(4):1048–1053PubMedCrossRef

32.

Torta R, Scalabrino A, Borio R (1998) Amisulpride e patologia cardiovascolare. G Ital Psicopatol 4(Suppl):107

Titel: Amisulpride in the short-term treatment of depressive and physical symptoms in cancer patients during chemotherapies
verfasst von: Riccardo Torta
Carlotta Berra
Luca Binaschi
Roberto Borio
Publikationsdatum: 01.05.2007
Verlag: Springer-Verlag
Erschienen in: Supportive Care in Cancer / Ausgabe 5/2007
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-006-0194-7

Springer Medizin

Amisulpride in the short-term treatment of depressive and physical symptoms in cancer patients during chemotherapies

Abstract

Introduction

Goals of work

Materials and methods

Main results

Conclusions

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie

Springer Medizin

Abstract

Introduction

Goals of work

Materials and methods

Main results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2007

Quality of life of Danish colorectal cancer patients with and without a stoma

Safety and efficacy of fentanyl administered by patient controlled analgesia in children with cancer pain

Demographic, medical, and psychosocial correlates to CAM use among survivors of colorectal cancer

Forthcoming Meetings

Oral mucositis and outcomes of allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies

Clinicians’ practice and attitudes toward cancer pain management in Korea

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie